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Abstract
We propose and evaluate a two-stage, phase 2, adaptive clinical trial design. Its
goal is to determine whether future phase 3 (confirmatory) trials should be conducted,
and if so, which population should be enrolled. The population selected for phase 3
enrollment is defined in terms of a disease severity score measured at baseline. We
optimize the phase 2 trial design and analysis in a decision theory framework. Our
utility function represents a combination of the cost of conducting phase 3 trials and,
if the phase 3 trials are successful, the improved health of the future population minus
the cost of treatment. Given such a utility function and a discrete prior distribution on
the conditional treatment effect, we compute the Bayes optimal adaptive design. The
resulting design is compared to simpler designs in simulation studies. We also apply
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the designs to resampled data from a completed, phase 2 trial evaluating a new surgical
intervention for stroke.
Keywords: Adaptive Enrichment Design, Backward Induction, Treatment Effect
Heterogeneity

1

Introduction

A new treatment may be effective only for a subset of the overall study population. This poses
important challenges for designing a randomized clinical trial to evaluate such a treatment.
On the one hand, ignoring participant heterogeneity and enrolling the overall population
can lead to a dilution of the treatment effect, and may create an unethical situation where
participants who do not benefit from the treatment are treated. On the other hand, enrolling
only a narrow proportion of the overall population would not answer the question of whether
the treatment benefits the larger population; furthermore, such restrictive enrollment could
lead to slower recruitment and longer trial duration.
Our work is motivated by a multicenter, randomized trial where the new surgical intervention called Minimally-Invasive Surgery Plus rt-PA for Intracerebral Hemorrhage Evacuation
(MISTIE) was compared to standard medical care (Hanley et al., 2016). An important baseline (i.e., pre-randomization) characteristic is intracerebral hemorrhage (ICH) volume, which
is one measure of disease severity. Based on their understanding of brain hemorrhage, the
clinical investigators conjectured that the new treatment may have different effects depending on a participant’s pre-randomization ICH volume. We compare different types of phase
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2, randomized trial designs whose goal is to inform a future recommendation about which
(if any) range of ICH volume should be used as the enrollment criterion in future phase 3,
confirmatory trials. For computational reasons, we discretize ICH volume by partitioning
the range of its possible values; in general, if one has a continuous-valued baseline score, our
approach can be applied to a discretized version of it.
We consider two-stage, adaptive enrichment designs for the phase 2 randomized trial.
Adaptive enrichment designs involve preplanned rules for modifying enrollment criteria based
on data accrued in an ongoing trial (Wang et al., 2009). We hypothesized that adaptive
enrichment in the phase 2 trial might be useful for making an optimal recommendation for
the population (if any) to enroll in future phase 3 confirmatory trials. In such a phase 2
design, information from the first stage of the phase 2 trial can be used to target who to
enroll in the second stage of the phase 2 trial. For example, if early phase 2 data indicated
a treatment benefit only for those with high baseline scores, participants near the boundary
of such scores could be oversampled in the second stage of the phase 2 trial; this may
lead to improved information for recommending which population to enroll in phase 3. We
investigate whether such an adaptive feature adds value (in terms of expected utility, defined
below) or not, compared to a non-adaptive phase 2 design.
Related work aimed at determining the population who benefits from a treatment includes, e.g., Jiang et al. (2007), Zhou et al. (2008), Barker et al. (2009), Freidlin et al.
(2010), Lee et al. (2010), Kim et al. (2011), Cai et al. (2011), Lai et al. (2014), Xu et al.
(2014), Ohwada and Morita (2016), Spencer et al. (2016). Our approach differs from these in
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that we explicitly define the performance goal of our phase 2 design (the objective function)
in a decision theory framework and compute the Bayes optimal adaptive enrichment design
over a class of designs defined in Section 2.
We next discuss related work that uses a decision theory approach for optimizing trial
designs. Colton (1963, 1965) aim to select the best of two treatments; Banerjee and Tsiatis
(2006) aim to minimize expected sample size; Cheng and Berry (2007) aim to maximize the
expected number of effectively treated participants in the trial; Hampson and Jennison (2015)
aim to optimize power to detect the best of multiple treatments. Each of the aforementioned
references involves a single population. In contrast, we consider multiple populations defined
by a baseline score, and aim to determine which population (if any) to recommend for a pair
of future phase 3 trials. Our designs also differ from the above related work in terms of the
types of designs we consider, i.e., phase 2 designs that can adapt the population enrolled
(called adaptive enrichment). The work of Graf et al. (2015), Krisam and Kieser (2015),
Götte et al. (2015), and Rosenblum et al. (2016) involves adaptive enrichment using a binary
biomarker that divides participants into two subpopulations. In contrast, by allowing the
population selected for phase 3 to be an interval of the baseline score, we allow a larger
number of possible subpopulations.
In Section 2, we define the class of trial designs that we optimize over. The trial design
optimization problem and our approach to solving it are given in Section 3. In Section 4,
we use simulations to compare the performance of an optimized, two-stage, adaptive design
versus an optimized (non-adaptive) one-stage design. The main result is that the two-stage,
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adaptive design did not improve expected utility, where the utility function measures the
quality of the recommendation for who to enroll in future phase 3 trials; however, as shown
in Section 4.4, the two-stage, adaptive design leads to fewer participants assigned to a nonefficacious or harmful treatment during phase 2. We apply the designs to resampled data
from a completed, phase 2 trial (MISTIE II) evaluating a new surgical intervention for stroke,
in Section 5. In Section 6, we present areas for future research.

2

Data Generating Process and Phase 2 Trial Designs

2.1

Overview of Fixed and Adaptive Designs

The populations we consider are based on a predefined variable that is obtained by discretizing a continuous-valued baseline score. The score could measure, e.g., disease severity. Our
running example is pre-randomization ICH volume in the MISTIE II trial.
We focus on phase 2 randomized trials comparing a new treatment to standard of care
(control) with a 1:1 randomization ratio. We compare two-stage, adaptive enrichment designs
versus one-stage, fixed designs. Both designs have the same total sample size (denoted as
2n), and have the goal of making an optimal recommendation for the population (if any) to
enroll in two, future phase 3 trials. Two, future phase 3 trials are considered since this is
what the U.S. Food and Drug Administration typically requires for approval of a new drug;
the phase 3 trials are assumed to be fixed (non-adaptive) and have predefined sample size
N.
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Figure 1 illustrates two types of phase 2 designs: the one-stage, fixed design and the
two-stage, adaptive enrichment design, referred to as the fixed design and adaptive design,
respectively. In the fixed design, shown in Figure 1a, 2n participants are enrolled from the
overall population. A preplanned rule is then applied to the data from this trial, in order to
select the population to enroll in two, future phase 3 trials. The population is defined by a
range of the baseline score.
The adaptive design, shown in Figure 1(b), has two stages. In Stage A, n participants are
recruited from the overall population. At the end of Stage A, a decision is made as to which
population to enroll in Stage B, in terms of the baseline score. This allows an enrollment
modification for Stage B (which always has n participants), with the goal of providing more
targeted information to help in the population selection at the end of Stage B for the future
phase 3 trials.
For both the fixed and adaptive phase 2 designs, the data from the 2n participants are
ultimately used to select a range of the baseline score to set as the enrollment criterion
for 2 future phase 3 trials. If the range selected is the empty set, this corresponds to not
conducting any phase 3 trials; this option is important since one of the main goals of phase
2 is to weed out useless treatments.
For the phase 2 adaptive design, the only feature that is adapted is the Stage B enrollment
criterion. The decisions involved in the phase 2 adaptive designs are:

(i) after collecting the Stage A data, what the enrollment criterion will be for Stage B;
(ii) after Stage B data has been collected, what will be the enrollment criterion for the
6
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(a) Fixed Design, 2n participants are enrolled in phase 2 from the overall
population. At the end, a recommendation of the population (if any) to
enroll in two, future phase 3 trials is made.

(b) Adaptive Design, n participants are enrolled in each of Stages A and B
in phase 2 with the Stage B enrollment criterion depending on the results
of Stage A. After Stage B, a recommendation of the population (if any) to
enroll in two, future phase 3 trials is made.

Figure 1: Phase 2 fixed design (top-left) and phase 2 adaptive design (bottom-left), each of
which may be followed by two phase 3 trials.
future phase 3 trials.
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2.2

Data Collected on Each Participant

Let R denote the continuous-valued baseline score, e.g., ICH volume in the MISTIE trial
example. We assume the population distribution of R is uniform on the interval (0, 1), which
can be achieved by a quantile transformation of any continuous variable. In order to make
our computations feasible, we discretize R by partitioning (0, 1) into M consecutive, equal
length intervals. Let R̃ = dRM e denote the corresponding interval number, which has values
in {1, . . . , M }. We refer to R̃ as the discrete score.
Let T denote the treatment arm indicator, where T = 1 means assignment to treatment
and T = 0 means assignment to control. Let Y ∈ R denote the primary outcome, which
we assume to be measured on each participant relatively soon after her/his enrollment. Let
∆ : (0, 1) → R denote the conditional treatment effect function ∆(r) = E(Y |T = 1, R =
r) − E(Y |T = 0, R = r) given the continuous-valued baseline score r ∈ (0, 1). Define the
discrete analog of ∆, which represents the average treatment effect for stratum R̃ = r̃, as:
˜
∆(r̃)
= E(Y |T = 1, R̃ = r̃) − E(Y |T = 0, R̃ = r̃) = M

Z

r̃/M

∆(r)dr,

(1)

(r̃−1)/M

for any r̃ ∈ {1, . . . , M }.
Conditional on the discrete baseline score and treatment indicator, the primary outcome
Y is assumed to be a random, independent draw from a normal distribution with common variance σ 2 . That is, we assume the conditional distribution of Y |T = t, R̃ = r̃ is
˜
Normal(µt (r̃), σ 2 ), for unknown mean functions µ0 (r̃), µ1 (r̃) satisfying µ1 (r̃) − µ0 (r̃) = ∆(r̃)
˜
and common, conditional variance σ 2 . For simplicity, we assume µ1 (r̃) = ∆(r̃)/2
and
˜
µ0 (r̃) = −∆(r̃)/2.
8
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The data vector contributed by each participant i, used as input to the decision rules
in the trial design, is denoted Vi = (R̃i , Ti , Yi ). Let X (A) and X (B) denote the sets of data
vectors Vi collected during Stage A and Stage B, respectively. Let X = (X (A) , X (B) ) denote
the entire data set at the end of Stage B.

2.3

Definition of Phase 2 Adaptive Designs

Let E (A) and E (B) denote the allowed enrollment choices at the end of Stage A and Stage B,
respectively. The action sets E (A) , E (B) each consist of a prespecified, finite set of intervals
(rl , ru ) with endpoints rl , ru ∈ {0, 1/M, 2/M, . . . , 1} and rl ≤ ru ; each interval represents
a range of the baseline score. If the interval (rl , ru ) ∈ E (A) is selected at the end of Stage
A, it means that n participants will be enrolled during Stage B using inclusion criterion
R ∈ (rl , ru ). If the interval (rl , ru ) ∈ E (B) is selected at the end of Stage B, it means that
the two, phase 3 trials will enroll N participants using inclusion criterion R ∈ (rl , ru ). We
assume that E (A) contains the full interval (0, 1) and that E (B) = E (A) ∪ {∅}, where the empty
set ∅ represents not conducting any phase 3 trials. By convention, we represent the empty
set by an interval (rl , ru ) with rl = ru .
An adaptive design is defined as a pair of decision rules (d(A) , d(B) ), where d(A) is a map
from the Stage A data X (A) to the set of enrollment choices E (A) and d(B) is a map from
the cumulative data X to E (B) . We assume these maps are measurable, which is generally
required for adaptive designs (Liu et al., 2002). Whenever maxima are taken over pairs of
decision rules (d(A) , d(B) ), it is assumed that this is over all possible pairs of such measurable
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maps.
After collecting the Stage A data X (A) , the prespecified decision rule d(A) is applied to
select the action from E (A) ; this determines the population to be enrolled during Stage B.
At the end of Stage B, the cumulative data X = (X (A) , X (B) ) has been collected, and the
prespecified decision rule d(B) is applied to determine the action in E (B) ; this action represents
the enrollment criterion for the two, future phase 3 confirmatory trials. The fixed design is
a special case of the adaptive design with d(A) always mapping to the action (0, 1).

2.4

Prior Distribution on Conditional Treatment Effect Function

We assume a prior π on the conditional treatment effect function ∆. In our simulations, π
is set to be a finite set of point masses on the functions ∆ = δ1 , . . . , δ6 , shown in Figure 2.
We refer to each δk as a possible state of nature.
In Figure 2, the function δ1 represents the conditional treatment effect being 1 for all values of the baseline score R in (0, 1). The function δ2 represents the treatment only benefiting
the population with baseline scores greater than 1/2, while the function δ4 represents the
treatment benefiting the population whose baseline scores are between 1/4 and 3/4. Under
the conditional treatment effect function δ5 , the treatment benefit is −1, i.e., the treatment
is harmful, for all values of the baseline score. Under δ6 , there is zero treatment benefit for
every baseline score value; this represents the global null hypothesis of no treatment effect for
any stratum of the baseline score. The discretized versions of δ1 , . . . , δ6 , based on applying
(1) to each, are given in Table 5 of the Supplementary Material.
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Figure 2: Six states of nature δ1 , . . . , δK . The solid line represents the treatment effect
function δk , while the dashed line is a horizontal zero line as a reference.
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3

Optimization Problem and Algorithm to Solve It

3.1

Utility Function

Our utility function focuses on what happens as a consequence of the phase 2 trial. It
represents a combination of the cost of conducting phase 3 trials (if they are recommended
after phase 2) and the improved health of the future population minus the treatment’s cost
(if the phase 3 trials succeed). The utility function U (rl , ru ; ∆) takes the function ∆ and an
action (rl , ru ) ∈ E (B) (which represents the interval recommended for phase 3 enrollment) as
inputs, and is defined as follows: if no phase 3 trials are recommended (which occurs when
rl = ru ) then U (rl , ru ; ∆) = 0, and otherwise U (rl , ru ; ∆) equals

Treatment Benefit


}|
{
z
Treatment
Cost

 zPhase}|3 Cost{
 Z ru
z }| { 
∆(r)dr − c(ru − rl )
− λ/(ru − rl ), (2)
P (2 Phase 3 Trials Succeed|∆, rl , ru ) ×


rl




where P (2 Phase 3 Trials Succeed|∆, rl , ru ) is the conditional probability, defined below,
that both phase 3 trials enrolling those with baseline scores in (rl , ru ) succeed given ∆.
The components in curly braces in (2) represent the population health and treatment
cost due to the treatment being approved (after 2 successful phase 3 trials) for use in the
population with baseline scores in the range (rl , ru ). The term

R ru
rl

∆(r)dr represents the

health benefit that would result from the population with baseline score in the interval
(rl , ru ) using the treatment instead of the control. This term is maximized if the interval
(rl , ru ) contains precisely those who benefit from treatment (and possibly also those who
have no effect from treatment).
The second term in curly braces c(ru − rl ) represents health system costs to the future
12

http://biostats.bepress.com/jhubiostat/paper290

population if both phase 3 trials succeed leading to the drug being approved and used by
the recommended population (rl , ru ). Here, c is a constant, and we assume that the health
system cost is proportional to the size of the population with baseline score in (rl , ru ). We
use the term “cost” in the general sense that captures negative impacts of administering the
treatment to a future population. For example, cost may reflect monetary cost and negative
impacts in terms of frequency and severity of side effects caused by treatment. If the cost
c > 0, then there is a penalty for approving the treatment for any stratum r ∈ (0, 1) whose
treatment effect ∆(r) is less than c; in particular, it penalizes for approving the treatment
for strata who have zero treatment effect (unlike the first term in curly braces).
The component P (2 Phase 3 Trials Succeed|∆, rl , ru ) is the probability of success of two,
future phase 3 trials enrolling from the population with baseline score in the interval (rl , ru ).
Assuming that the two phase 3 trials are independent given (rl , ru ), this probability is the
squared power of a fixed (non-adaptive) design for the phase 3 trial where the average
treatment effect is (ru − rl )−1

R ru
rl

∆(r)dr, i.e., the average height of the treatment effect

curve ∆ over the interval (rl , ru ). The prespecified sample size N for each phase 3 trial is
determined by the minimum, clinically meaningful benefit ∆min , type I error, type II error,
and outcome variance σ 2 .
The last term of the utility function, λ/(ru − rl ), is proportional to the duration of
each phase 3 trial enrolling participants with baseline scores in (rl , ru ), where we made
the approximation that the enrollment rate is proportional to the size of the recommended
population to be enrolled. This could apply, for example, to the MISTIE trial where ICH
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volume is only determined after recruitment based on neuroimaging, and so excluding more
participants would require longer recruitment to reach the total sample size N .
Though Type I error control in the phase 2 trial is not our focus, we do evaluate design
performance when there is no treatment effect to determine how often future phase 3 trials
are (erroneously) recommended.

3.2

Optimization Problem

The goal is to compute the pair of optimal decision rules at the end of Stage A and at
(A)

(B)

the end of Stage B in phase 2, denoted by dopt and dopt , respectively. These are the rules
that maximize expected utility, where the expectation is with respect to the distribution of
(∆, X) induced by the prior π on ∆. Define
 


(A) (B)
(dopt , dopt ) = argmax E U d(B) X (A) , X (B) [d(A) {X (A) }] ; ∆ ,

(3)

d(A) ,d(B)

where the maximum is taken over all pairs (d(A) , d(B) ) of decision rules as defined in Section 2.3. Throughout, expectation E and probability P are with respect to the prior π and
a generic phase 2 adaptive design (d(A) , d(B) ) unless indicated otherwise. As described in
Section 3.1, the utility U depends on the action d(B) (X) taken at the end of Stage B (i.e.,
who to enroll in the future phase 3 trials) and the conditional treatment effect function ∆.
The action taken at the end of Stage B depends on the data from Stages A and B, i.e.,
X = (X (A) , X (B) ). We write X (B) = X (B) [d(A) {X (A) }] in the display above to make explicit
that the Stage B data generating distribution depends on the decision d(A) {X (A) } at the
end of Stage A regarding the population to be enrolled during Stage B. This highlights the
14
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sequential nature of the decision problem.

3.3

Algorithm to Solve the Optimization Problem

Banerjee and Tsiatis (2006), Cheng and Berry (2007) and Hampson and Jennison (2015)
used backward induction to provide closed form solutions to their optimal adaptive designs
under a decision-theoretic framework. Since this is not possible in our problem, we instead
use backward induction with Monte-Carlo forward simulation. Such backward induction
has been implemented to solve problems in different contexts by, e.g., Carlin et al. (1998),
Brockwell and Kadane (2003), Rossell et al. (2006), Ding et al. (2008).
Let n(j) (r̃) denote the cumulative sample size per arm for participants with baseline score
R̃ = r̃ enrolled during or before Stage j ∈ {A, B} of the phase 2 trial, for each r̃ ∈ {1, . . . , M }.
We assume that in Stage A, n/M are enrolled from each baseline stratum r̃ ∈ {1, . . . , M }. For
Stage B of the adaptive design, we assume an equal number are enrolled from each stratum
r̃ contained in the selected population d(A) (X (A) ), such that a total of n are enrolled in that
stage. We assume that within each stage and enrolled stratum of the baseline score, an equal
number are assigned to treatment and control; this can be accomplished (approximately) by
stratified block randomization.
Define the sample mean difference between arms of the primary outcome using cumulative
data through the end of Stage j for participants with R̃ = r̃ as
b (j) (r̃) = 1
∆
n(j) (r̃)

(
X

)
1(Ti = 1, R̃i = r̃)Yi −

i

X

1(Ti = 0, R̃i = r̃)Yi

,

i

where the summations are over the participants i with outcomes observed at or before the
15
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end of Stage j, and 1(S) is the indicator variable taking value 1 if S is true and 0 otherwise.
b (j) (r̃) is an estimator of ∆(r̃), the average treatment effect in stratum r̃. Let
The statistic ∆
b (j) denote the vector of cumulative sample mean differences for each category of baseline
∆
score r̃ ∈ {1, . . . , M } using all data up through the end of Stage j ∈ {A, B}.
We next define minimal sufficient statistics S̃ (A) , S̃ (B) for ∆ based on the data X (A) available at the end of Stage A and the data X available at the end of Stage B, respectively. Stage
b (A) , i.e., the sample mean differences
A is equivalent to a fixed design, and we define S̃ (A) = ∆
within each stratum r̃ ∈ {1, . . . , M }. Since Stage B involves a potential enrollment modifib (B) ).
cation that is determined by the decision d(A) (X (A) ), we define S̃ (B) = (d(A) (X (A) ), ∆
Backward induction starts from the end of Stage B, where we have collected the overall
data X = (X (A) , X (B) ). The first step is to maximize the conditional expected utility over
all possible Stage B decision rules given X. It follows from (3) that
(B)

dopt (X) = argmax E[U {d(B) (X); ∆}|X],

(4)

d(B)

where the expectation is with respect to the distribution of ∆ given X.
We assume the prior distribution π on ∆ consists of K point masses δ1 , . . . , δk , each
representing a conditional treatment effect function. For any candidate action (rl , ru ) ∈ E (B) ,
Monte Carlo simulation is used where we draw posterior samples of ∆ given the data X
in order to approximate the conditional expected utility if this action is followed. i.e.,
E[U (rl , ru ; ∆)|X], . The posterior distribution P (∆ | X) depends on the data X only
through the sufficient statistics S̃ (B) . Given the data X, we compute the corresponding
sufficient statistics S̃ (B) and then draw posterior samples of ∆ from P (∆ | S̃ (B) ) as described
16
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below.
Consider any Stage A decision rule d(A) and data vector X = (X (A) , X (B) ) that can be
generated under the phase 2 adaptive design using Stage A decision rule d(A) . Let E =
d(A) (X (A) ) denote the decision at the end of Stage A; without loss of generality, we assume
ˆ (A) . We prove the
d(A) depends on the data X (A) only through the sufficient statistic ∆
following in the Supplementary Material, where ∝ represents proportionality with respect
to functions of the data X:
b (B) = ∆
b (B) (X) | ∆ = δk )P (∆ = δk ),
P (∆ = δk | X) ∝ P E (∆

(5)

where P e denotes the probability density function of X under the deterministic (nonadaptive) Stage A decision rule that always enrolls population e ∈ E (A) during Stage B
regardless of the Stage A data. The above display reduces (up to a proportionality constant)
the problem of computing P (∆ = δk | X) to the following simpler problem: computing the
conditional probability density that the cumulative sample mean differences (at the end of
b (B) (X) given ∆ under the non-adaptive Stage A decision rule that always
Stage B) equal ∆
enrolls population E = d(A) (X) during Stage B.
(B)

We describe how to compute dopt (X) given X. Under the probability density P E , the
b (B) conditional on ∆ = δk has a multivariate normal distribution with mean vector
statistic ∆
determined by integrating δk over each interval ((m − 1)/M, m/M ) : m = 1, . . . , M using the
formula on the right side of (1) and covariance matrix Σ the diagonal matrix with zeros off
the main diagonal and Σmm = 2σ 2 /n(B) (m) for each m = 1, 2, . . . , M . Given the observed
b (B) , for each k = 1, . . . , K we compute the density P E (∆
b (B) = ∆
b (B) (X) | ∆ = δk ) from this
∆
17
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multivariate normal distribution and multiply by the prior P (∆ = δk ) to obtain the right side
of (12), which was shown above to be proportional to the posterior probability P (∆ = δk |
X). For each interval (rl , ru ) in the action space E (B) , we repeatedly draw from this posterior
distribution to approximate the posterior expected utility

P

k≤K

U (rl , ru ; δk )P (∆ = δk | X),
(B)

which is E[U {d(B) (X); ∆}|X] under the decision d(B) (X) = (rl , ru ). We set dopt (X) to be
the interval (rl , ru ) in E (B) that gives the maximum posterior expected utility.
(A)

(B)

The derivation of dopt is analogous to that of dopt , and is described in the Supplementary
Material. All of the above computations were implemented in R (R Core Team, 2015).

4

Simulation Study with Six Possible Treatment Effect
Curves

4.1

Simulation Setup

We implement the optimization algorithm from the previous section in a simulation study
comparing the performance of the fixed versus adaptive phase 2 design. The prior π on ∆
is a discrete distribution on the conditional treatment effect curves {δk }6k=1 in Figure 2 that
places 50% weight on δ6 (the global null hypothesis) and equal weights on δ1 , . . . , δ5 . We
allocate greater weight to δ6 in order to reflect the realistic possibility that an experimental
treatment has no effect at all. Intuitively, the impact of having greater weight on δ6 is that
the corresponding optimal design will be more conservative in initiating phase 3 follow-up
trials, thereby saving resources at the cost of lowering the chance of successful phase 3 trials.
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The prior π is one possible choice; our general approach can be applied to an arbitrary
set of weights and any finite set of conditional treatment effect functions, i.e., applied to any
prior consisting of a finite set of point masses. The choice of prior would ideally be chosen
based on prior scientific knowledge and data from earlier studies. Here we demonstrate a
relatively simple case as a proof of concept.
For a given state of nature ∆, the population who benefit from treatment is defined as
{r ∈ (0, 1) : ∆(r) > 0}. For example, under ∆ = δ2 , the treatment benefits precisely those
with r ∈ (0.5, 1). Depending on which of δk , k = 1, . . . , 6, is the true state of nature, the
population who benefit from treatment is an interval of the baseline score r in the set
E (B) = {(0, 1), (0.5, 1), (0, 0.5), (0.25, 0.75), ∅}.

(6)

Let
E (A) = {(0, 1), (0.5, 1), (0, 0.5), (0.25, 0.75)}.
We use the above sets E (A) , E (B) as the action sets for our decision problem, representing
the possible choices for who to enroll next based on the data at the end of Stages A and B,
respectively.
We define R̃ to have M = 4 levels corresponding to the baseline score being in the
intervals (0, 0.25), (0.25, 0.5), (0.5, 0.75), (0.75, 1), respectively. We chose this discretization
since any non-empty interval in E (A) or E (B) can be represented as a union of these intervals
(ignoring the interval endpoints).
We selected the phase 2 total sample size, denoted 2n, to be 528. This was, roughly,
based on the sample size required for the fixed design (Figure 1a) to have type I error α
19
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and power 1 − β, in the simple case of a constant conditional treatment effect ∆ = τ > 0
and conditional variance σ 2 . This sample size is 4{Φ−1 (1 − α) + Φ−1 (1 − β)}2 (σ 2 /τ 2 ); to
maintain a realistic signal to noise ratio in the phase 2 trial, we set α = 0.1, β = 0.2, σ 2 = 9
and τ = 0.554 in this formula (and rounded down), which implies the total phase 2 sample
size is 2n = 528. Our choices of α, β are typical for phase 2 trials as described by Rubinstein
et al. (2005). However, our choices of τ and σ were somewhat arbitrary; the value of τ was
taken to be between the average treatment effect of 1 (under ∆ = δ1 ) and 0.25 (under each
∆ = δk , k = 2, 3, 4). We set the prespecified sample size N = 5564 for each phase 3 trial
based on the above formula with parameters τ = 0.2 (representing the minimum, clinically
meaningful benefit), type I error α = 0.05, type II error β = 0.2, and outcome σ = 3.
Our optimization problem is invariant to rescaling in that the optimal decision rules (as
functions of the sufficient statistics S̃ (A) , S̃ (B) ) are unchanged if we multiply all of n, σ 2 , N
by the same positive constant. For example, the optimal decision rules would be the same
if we multiply these parameters by 1/4, i.e., setting the phase 2 total sample size 2n = 132,
outcome conditional variance σ 2 = 9/4, and phase 3 sample size N = 1391.

4.2

Optimal Adaptive Phase 2 Designs in Simulation Study
(A)

(B)

The optimal decision rules dopt and dopt are defined by (3), which depends on the prior π
and the utility function U defined above. These rules are optimal for a pair (π, U ) in terms
of the Bayes criterion (3). These rules may be suboptimal for any single state of nature δj ,
since the rules find the best tradeoff in expected utility U across these different states of
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nature, where the relative importance of each state of nature depends on π. The optimal
decision rules were computed using the backward induction method in Section 3.3.
(A)

(B)

We explored the performance of the optimal decision rules (dopt , dopt ) by conducting
simulated trials with data generated from one treatment effect function δk at a time. For
each δk , we simulated 200 trials under ∆ = δk and using the precomputed decision rules
(A)

(B)

(dopt , dopt ). The frequency of each population in E (A) getting selected for Stage B enrollment
was recorded; also recorded was the frequency of each population in E (B) getting selected for
(A)

(B)

the future phase 3 trials. The optimal rules dopt and dopt depend on the prespecified π and
U , and are the same functions regardless of our setting ∆ to be different curves δ1 , . . . , δk in
the simulation study.
Table 1 shows the operating characteristics of the optimal, adaptive phase 2 design
(A)

(B)

(dopt , dopt ) using the utility function (2) with λ = 0.01, c = 0.32. The top half of Ta(A)

ble 1 shows the frequency of different choices for Stage B enrollment corresponding to dopt .
For example, 34% of the simulated trials recommend to enroll participants from the overall
population in Stage B of the phase 2 adaptive design when ∆ = δ1 is the data generating
distribution. For δ2 and δ3 , where only half of the overall population benefits from the treatment, there is a 67% chance of enrolling at least the population who benefit from treatment
in Stage B.
The bottom half of Table 1 shows the frequency of different choices for the population
(B)

to enroll in the two, phase 3 trials under the decision rule dopt . We underline the number
corresponding to the population who benefit from treatment (defined in Section 4.1) under
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(A)

(B)

Table 1: Operating Characteristics of dopt (top) and dopt (bottom) for λ = 0.01, c = 0.32.
(A)

Distribution of Population Recommended for Stage B Enrollment by dopt
(A)

(A)

dopt = (0, 1) dopt = (0.5, 1)

(A)

(A)

dopt = (0, 0.5)

dopt = (0.25, 0.75)

∆ = δ1

0.34

0.27

0.24

0.15

∆ = δ2

0.30

0.37

0.21

0.12

∆ = δ3

0.34

0.22

0.33

0.11

∆ = δ4

0.27

0.26

0.26

0.21

∆ = δ5

0.67

0.14

0.13

0.06

∆ = δ6

0.30

0.34

0.27

0.09
(B)

Distribution of Population Recommended for Phase 3 trials by dopt
(B)

(B)

dopt = (0, 1) dopt = (0.5, 1)

(B)

(B)

(B)

dopt = (0, 0.5) dopt = (0.25, 0.75) dopt = ∅

∆ = δ1

0.96

0.01

0.01

0.02

0.00

∆ = δ2

0.07

0.53

0.04

0.09

0.27

∆ = δ3

0.11

0.02

0.56

0.09

0.22

∆ = δ4

0.12

0.04

0.09

0.40

0.35

∆ = δ5

0.00

0.00

0.00

0.00

1.00

∆ = δ6

0.01

0.09

0.06

0.12

0.72

the corresponding treatment effect function δk . We mark in bold the largest proportion in
each row, which represents the population that is recommended most frequently for the future
phase 3 trials. For example, when data is generated under treatment effect function δ2 (row
2), the proportion 0.53 is both underlined and in bold, which means that the corresponding
22

http://biostats.bepress.com/jhubiostat/paper290

(B)

Table 2: Operating Characteristics of dopt for λ = 0.01, c = 0.34.
(B)

Distribution of Population Recommended for Phase 3 trials by dopt
(B)

(B)

dopt = (0, 1) dopt = (0.5, 1)

(B)

(B)

(B)

dopt = (0, 0.5) dopt = (0.25, 0.75) dopt = ∅

∆ = δ1

0.95

0.01

0.02

0.02

0.00

∆ = δ2

0.07

0.48

0.04

0.08

0.33

∆ = δ3

0.09

0.03

0.55

0.08

0.25

∆ = δ4

0.11

0.05

0.07

0.39

0.38

∆ = δ5

0.00

0.00

0.00

0.00

1.00

∆ = δ6

0.01

0.07

0.05

0.08

0.79

population (0.5, 1) is the population who benefits and is the population most frequently
recommended for phase 3 trials. In every row in Table 1, the bold number coincides with the
underlined number, which shows that in the plurality of simulated trials the optimal design
chooses the population who benefits.
The results in Table 1 are for a particular choice of utility function parameters λ and
c, which encode the relative importance of the cost of conducting phase 3 trials and the
treatment cost if the treatment is approved (including both financial costs and health costs
such as side effects), respectively. We next show the impact of increasing c from 0.32 to 0.34,
while holding all other parameters constant. Using the utility function (2) with λ = 0.01, c =
(B)

0.34, we computed the operating characteristics of the component dopt of the optimal design,
summarized in Table 2. There is a higher chance of making the decision not to conduct any
phase 3 trials (rightmost column), compared to Table 1, under each δk (except δ5 where
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no phase 3 trials are conducted with probability 1 in both tables). Under the global null
hypothesis ∆ = δ6 , the probability of conducting phase 3 trials (which would be a waste of
resources) drops from 28% to 21% comparing c = 0.32 to c = 0.34. The tradeoff is that the
optimal decision rule for c = 0.34 (Table 2) has lower probabilities of selecting the optimal
population for enrollment in phase 3 when the overall population or a subpopulation benefits
(∆ ∈ {δ1 , δ2 , δ3 , δ4 }).

4.3

Optimal Adaptive versus Fixed Phase 2 Trial Design

We solved the same optimization problem as in Section 4.2 using λ = 0.01, c = 0.32, except
restricting to a fixed design, i.e., setting d(A) to be the constant function that always selects
the full population (0, 1) to enroll in Stage B of phase 2; only the function d(B) is optimized.
The resulting design is referred to as the optimal fixed design. We compare its performance
to that of the optimal adaptive phase 2 design in order to determine the value added by
adaptive enrichment, i.e., the value added by allowing enrollment to be restricted to a subset
of the population in Stage B of phase 2.
The recommendation frequencies for phase 3 trials for the optimal fixed design are very
similar to those for the optimal adaptive design in Table 1, with the maximum difference
between any 2 corresponding entries being 3%. Also, we computed the expected utility for
the optimal adaptive design versus the fixed design, based on 15,000 simulated trials. The
expected utility is 0.07 for both designs. We also compared the contribution from each
component of the utility function for these two designs, summarized in Table 3.
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Table 3: Expected utility and expected value of its 4 components under the optimal fixed
design and adaptive designs, respectively, based on the simulation setup in Section 4.1 using
λ = 0.01, c = 0.32. Expectation is with respect to the prior π. The interval (rl , ru ) in the
(B)

formulas below represents the phase 3 enrollment decision dopt (X).
Fixed Design Adaptive Design
Expected Utility E[U ]

0.07

0.07

Rr
Expected Treatment Benefit E[ rlu ∆(r)dr]

0.14

0.14

Expected Treatment Cost E[c(ru − rl )]

0.10

0.10

P (2 Phase 3 Trials Conducted and Both Succeed)

0.27

0.27

Expected Phase 3 Cost E[λ1(rl 6= ru )/(ru − rl )]

0.82

0.80

Components of Expected Utility:

The probability of having 2 successful phase 3 trials is 0.27, averaged over the prior π.
This is the probability of successfully demonstrating treatment efficacy when considering the
combined phase 2/3 trial sequence. This may seem like a low probability of the trial sequence
succeeding. However, we next show that our choice of prior π implies that regardless of what
is done during phases 2 and 3 (e.g., even if both sample sizes were arbitrarily increased), there
is no way to achieve a probability greater than 41% of having a successful trial sequence.
Intuitively, this is because the prior selects ∆ = δ5 or ∆ = δ6 with probability 0.6, and in
such cases the treatment is not beneficial for any stratum of the baseline score.
We upper bound the probability of two successful phase 3 trials under the prior π and
an arbitrary rule for deciding which population to enroll in phase 3. Under π, the event
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maxr∈(0,1) ∆(r) ≤ 0, which occurs when ∆ is δ5 or δ6 , has probability 0.6. On this event,
there is at most 0.05 probability of each phase 3 trial succeeding. Therefore, the probability
of two successful phase 3 trials (regardless of both the decision rule for phase 3 enrollment
and the phase 3 sample size) is at most 1 − 0.6(1 − 0.052 ) = 0.4015. By comparison, the
corresponding 0.27 probability for the utility-maximizing designs above (where the objective
function involves terms other than just power in phase 3) is not insubstantial.

4.4

Impact of Adaptive Design on Number Assigned to Superior
Treatment During Phase 2

In this section, we shift our focus to what happens to participants during phase 2, rather
than after phase 2. Specifically, we measure the impact of being enrolled in the phase 2
trial compared to not being enrolled; we assume not being enrolled in the trial means that
a patient would have received the standard of care, i.e., the control. We focus only on Stage
B participants in the phase 2 trial since our goal is to contrast the fixed versus adaptive
designs, and these designs have identical patient outcome distributions during Stage A.
We say that Stage B participant i with baseline score Ri in study arm Ti is assigned to a
superior treatment (compared to control) if ∆(Ri ) > 0 and Ti = 1, that is, if the conditional
treatment effect is positive in that participant’s baseline stratum and she/he is assigned to the
treatment arm Ti = 1. For example, if ∆ = δ2 , each participant i with baseline score Ri > 0.5
in arm Ti = 1 is assigned to a superior treatment. We denote the proportion of Stage B
participants who are assigned to a superior treatment as fprop =

1
n

P

i

1{Ti = 1, ∆(Ri ) > 0},
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where the sum is over the n Stage B participants. Similarly, define the average benefit
to Stage B participants of being enrolled in the trial compared to not being enrolled, as
fben =

1
n

P

i

1(Ti = 1)∆(Ri ), where the sum is over the n Stage B participants.

Table 4 presents the expected proportion E(fprop |∆) of Stage B participants who are
assigned to a superior treatment and the expected average benefit E(fben |∆), respectively,
conditional on the treatment effect function ∆. These expectations depend on the decision
(A)

rule d(A) . We evaluated the optimal rule d(A) = dopt from Section 4.3, which was optimized
for the utility function U in (2) using λ = 0.01, c = 0.32. We also evaluate the fixed (nonadaptive) decision rule d(A) ≡ (0, 1). The evaluation of these decision rules was based on the
same set of simulations from Section 4.3.
For every treatment effect function δk where some but not all strata of r benefit from the
treatment (i.e., for δk : k ∈ {2, 3, 4}), the difference between the expected proportion assigned
(A)

to a superior treatment E(fprop |∆ = δ2 ) for dopt versus the fixed design is 3-5%, as shown
in Table 4. For the expected benefit fben , the relative improvement comparing adaptive
versus fixed designs ranges from (0.132 − 0.125)/0.125 ≈ 5% to (0.151 − 0.125)/0.125 ≈ 20%,
as we consider different δk .
Despite not providing a higher expected utility than the optimal fixed design (as shown
in Section 4.3), the adaptive design turned out to have advantages over the fixed design in
the number of participants assigned to a superior treatment in the phase 2 trial (which is
not reflected in the utility function from Section 3.1). That is, although the original aim
of the phase 2 adaptive design was to provide more targeted information to assist in the

27

Hosted by The Berkeley Electronic Press

Table 4: Expected value of fprop and fben , comparing fixed design versus adaptive design.
Top half shows E(fprop |∆ = δk ) and bottom half shows E(fben |∆ = δk ).
∆

Fixed Design Rule

Adaptive Design Rule

δ1

50%

50%

δ2

25%

29%

δ3

25%

28%

δ4

25%

30%

δ5

0%

0%

δ6

0%

0%

∆

Fixed Design Rule

Adaptive Design Rule

δ1

0.5

0.5

δ2

0.125

0.137

δ3

0.125

0.132

δ4

0.125

0.151

δ5

-0.5

-0.5

δ6

0.000

0.000

Data
Generating
E(fprop |∆ = δk ) :
Distributions

Data
Generating
E(fben |∆ = δk ) :
Distributions
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decision at the end of phase 2, a by-product is that the optimal adaptive design can lead
to more participants assigned to a superior treatment in phase 2. From this perspective,
such adaptive designs may be more ethical to conduct (under the assumptions built into our
simulation study).

5

Simulation Study Mimicking Features from the MISTIE
II Trial

We applied our optimized phase 2 designs in simulation studies where the data generating
distribution mimics features from the completed MISTIE II trial. The baseline score R is the
quantile of intracerebral hemorrhage (ICH) volume. A histogram of the pre-randomization
ICH volumes for MISTIE trial participants. We define M = 4 baseline score categories
demarcated by the 25%, 50% and 75% percentiles of ICH volume, which correspond to
33ml, 43ml, 57ml, respectively. The discrete baseline scores R̃ = 1, 2, 3, 4 correspond to the
ranges of ICH volume (in ml) [17, 33), [33, 43), [43, 57), [57, 120], respectively. The data
set consists of 90 participants with complete observations (R̃i , Ti , Yi ) : i = 1, . . . , 90 in the
MISTIE trial. The primary outcome is the indicator of whether the participant’s functional
disability score, as measured by the modified Rankin Scale, is 3 or less.
We consider adaptive phase 2 trial designs that are optimized for the problem setup in
Section 4.1 using sample size n = 64 per stage, and utility function parameters c = 0.1 and
(A)

(B)

each of λ ∈ {0.004, 0.01}; the resulting optimal designs are denoted dopt , dopt (which differ
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for the two different values of λ used). These optimization problems did not incorporate any
features of the MISTIE data except that the baseline score is discretized into 4 categories.
We investigated the performance of the above, optimized designs in simulated phase 2
trials where the distribution of the outcome Y given study arm T and baseline score R̃ is
˜
the empirical distribution in the MISTIE trial. The estimated treatment effects ∆(r̃)
from
this distribution are -0.07 for r̃ = (0, 0.25), 0.22 for r̃ = (0.25, 0.5), 0.12 for r̃ = (0.5, 0.75)
and 0.19 for r̃ = (0.75, 1).
Data in Stage A of each simulated phase 2 trial were generated as follows: equal numbers
from each baseline category were enrolled and assigned to each arm; for each participant i, a
random outcome Y was drawn from the MISTIE data set empirical distribution conditioned
on that participant’s study arm and baseline score (Ti , R̃i ). Stage B data were generated
analogously, except enrollment was only from the selected population.
The above data generating distribution violates our assumption that the outcome is
normally distributed conditional on the study arm and baseline score. Also, the induced
treatment effect function is not in the support of the prior π. This provided an opportunity
to evaluate the performance of our optimized phase 2 designs in a scenario that differs from
those it was optimized for.
Using the above data generating distribution, we simulated 200 phase 2 trials and computed the proportion of trials with each population recommendation for phase 3. The results
are summarized in Figures 3 and 4. In each figure, each rectangle’s base represents the interval corresponding to a population recommendation in E (B) for phase 3 enrollment, and its
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height represents the observed proportion of that recommendation under the optimal design
(B)

dopt . In Figure 3, for example, the population R̃ ∈ (0.5, 1) (base) is recommended for phase
3 enrollment in 30% (height) of simulated trials.
Figures 3 and 4, which differ only in the phase 3 duration cost λ = 0.004 vs. λ = 0.01,
show the impact of increasing this cost. This increase in λ incentivizes recommending a
broader population for phase 3 enrollment (to increase the enrollment rate) or recommending
no phase 3 trials. Comparing Figures 3 and 4, the overall population is recommended with
frequencies 4.5% vs. 8%, and no phase 3 trials are recommended with frequencies 17.5% and
32.5%, respectively.
Since we sampled data from the empirical distribution of the MISTIE II trial as described
˜
above, the true state of nature ∆(r̃)
is (−0.07, 0.22, 0.12, 0.19) for baseline ICH quartiles
r̃ = 1, 2, 3, 4, respectively. The population who benefit from treatment, in terms of baseline
ICH quartiles R̃, consists of the last 3 categories, which represent ICH volume quantiles
(0.25, 1]. Our phase 2 designs only allowed recommending a population to enroll in phase
3 from the action set E (B) defined in (6). This precluded enrolling the true population
who benefit from treatment (0.25, 1]. The allowed enrollment choices were the following:
(0, 1), which has the disadvantage of including the first quartile who are slightly harmed by
treatment; (0.5, 1) or (0.25, 0.75), each of which has the disadvantage of excluding a quartile
who benefit; (0, 0.5), which has both types of disadvantages; and the empty set. Each
(B)

optimized decision rule dopt in Figures 3 and 4 selects one of the most desirable options, i.e.,
one of (0.25, 0.75),(0.5, 1),(0, 1), with total probability ranging from 60-68.5%.
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Figure 3: The plot shows the proportion of simulated trials in which the optimized adaptive
phase 2 design makes each recommendation in E (B) for phase 3 trial enrollment, at λ = 0.004.
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Figure 4: The plot shows the proportion of simulated trials in which the optimized adaptive
phase 2 design makes each recommendation in E (B) for phase 3 trial enrollment, at λ = 0.01.
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6

Discussion

We optimized a phase 2 adaptive enrichment design where the utility function U represents
a combination of the cost of conducting phase 3 trials (if they are recommended after phase
2) and the improved health of the future population due to treatment minus the treatment’s
cost (if the phase 3 trials succeed). Despite not providing a higher expected utility than
the optimal fixed design, the adaptive design turned out to have advantages over the fixed
design in the number of participants assigned to a superior treatment in the phase 2 trial.
A limitation of our designs is that we require the primary outcome to be measured on
each participant relatively soon after her/his enrollment, in order to avoid a long pause in
enrollment between Stages A and B; this limitation is shared by many adaptive enrichment
designs.
In Section 4.1, we discretized the continuous-valued baseline score R into the 4 level
categorical variable R̃ by partitioning the support (0, 1) of R into 4 equal length intervals.
It may be possible to increase the expected utility of the optimal decision functions if we
modify the problem by using a finer discretization of (0, 1). Using a finer discretization,
e.g., consecutive intervals of width 1/8, could increase the information available about the
unknown value of ∆; this could be used to improve decisions and increase expected utility. A
tradeoff is that increasing the fineness of the discretization leads to increased computational
complexity. It is an area for future investigation to determine how much added value a finer
discretization provides, and at what computational cost.
An area for future research is to incorporate the possibility of early stopping for futility
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at the end of Stage A of phase 2, which could potentially save resources. We also could
consider sample sizes in Stage B of phase 2 that differ from the sample size in Stage A, or
that are adaptively selected based on Stage A data. Similarly, we could consider setting the
sample size for the phase 3 trials based on the data from phase 2. Another area for future
research is to consider a variety of different utility functions, e.g., incorporating the trial
design cost function from Emerson et al. (2011).
The R code for our computations in Section 4 and 5 is available at https://github.
com/duyu8411/Phase2AdaptDesign.
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Supplementary Material
Discretized versions of δ1 , . . . , δ6
Table 5 gives the discretized versions of δ1 , . . . , δ6 , based on applying (1) to each.
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˜
Table 5: Average treatment effect ∆(r̃)
in each stratum r̃ ∈ {1, 2, 3, 4}, under each possible
∆ = δ1 , δ2 , . . . , δ6 , as derived from Figure 2. In the row above the horizontal line, each
stratum r̃ is followed by the interval of the baseline score that it represents.

˜
˜ R̃)])
Average Treatment Effect ∆(r̃)
in Each Statum r̃ and Overall (E[∆(
r̃ = 1; (0, 0.25)

r̃ = 2; (0.25, 0.5) r̃ = 3; (0.5, 0.75) r̃ = 4; (0.75, 1)

Overall

∆ = δ1

1

1

1

1

1

∆ = δ2

0

0

0.25

0.75

0.25

∆ = δ3

0.75

0.25

0

0

0.25

∆ = δ4

0

0.5

0.5

0

0.25

∆ = δ5

-1

-1

-1

-1

-1

∆ = δ6

0

0

0

0

0

Proof of (5)
We prove (5) from Section 3.3.
P (∆ = δk | X) ∝ P (X | ∆ = δk )P (∆ = δk )

(7)

b (B) , d(A) (X (A) ), ∆
b (A) | ∆ = δk )P (∆ = δk )
∝ P (∆

(8)

b (B) , ∆
b (A) | ∆ = δk )P (∆ = δk )
= P E (∆

(9)

b (B) | ∆ = δk )P E (∆
b (A) | ∆
b (B) , ∆ = δk )P (∆ = δk )
= P E (∆

(10)

b (B) | ∆ = δk )P E (∆
b (A) | ∆
b (B) )P (∆ = δk )
= P E (∆

(11)

b (B) | ∆ = δk )P (∆ = δk ),
∝ P E (∆

(12)
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where (7) follows from Bayes’ rule; (8) holds since S̃ (B) is a sufficient statistic for ∆; (9)
follows from the sequential structure of the data generating process; (10) follows from the
b (B) is a sufficient statistic for ∆ in
definition of conditional probability; (11) follows since ∆
b (A) | ∆
b (B) )
the design that always enrolls population E in Stage B; (12) holds because P E (∆
does not depend on ∆, and thus is absorbed into the proportionality constant that depends
only on X.

(A)

Computation of dopt

At the end of Stage A, we have collected Stage A data X (A) . The goal at this point in the
backward inductive computation is to maximize the expected utility conditioned on X (A)
(B)

over all possible Stage A enrollment choices E (A) , assuming that dopt will subsequently be
(A)

used after Stage B; the maximizer is defined as dopt (X (A) ). It follows from (3) that
(A)
dopt (X (A) )

h

n
o
i
(B)
(A)
= argmax E U dopt (X); ∆ X
d(A)

h

n
 o (A) i
(B)
(A)
(B) (A)
(A)
= argmax E U dopt X , X [d {X }] ; ∆ X
,

(13)

d(A)

where the expectation is with respect to the conditional distribution of (∆, X (B) ) given the
(B)

Stage A data X (A) (which is induced by the prior π). Analogous to the computation of dopt ,
we use Monte-Carlo simulation to approximate the posterior conditional expectation in (13)
via the posterior distribution of (∆, X (B) ) given X (A) ,
(B)

Analogous to the computation of dopt , we use Monte-Carlo simulation to approximate
the posterior conditional expectation in (13) via the posterior distribution of (∆, X (B) ) given
X (A) , as described in the Supplementary Material. , where we first draw ∆ from the pos42
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terior distribution P ∆|X (A) via (12), and generate the Stage B data, X (B) , given ∆ and
a possible Stage A enrollment choice, d(A) (X (A) ), according to the data generating distribution specified in Section 2.2. We thus obtain the full data, X = (X (A) , X (B) ), and a
value for the utility function. The average values of the utility function from multiple such
draws of data approximates the posterior conditional expectation for this particular Stage
A enrollment choice. We consider each possible Stage A enrollment choice in E (A) , and set
(A)

the optimal Stage A enrollment decision dopt (X (A) ) to be the maximizer over E (A) of this
posterior conditional expectation.
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